

Merck asks EU regulator to authorize its COVID-19 pill

November 23 2021



This undated file image provided by Merck & Co. shows their new antiviral medication. The European Medicines Agency said it has received a request from Merck to authorize its coronavirus antiviral, the first pill shown to treat COVID-19. In a statement on Tuesday, Nov. 23, 2021, the EU drug regulator said it had started evaluating molnupiravir, made by Merck and Ridgeback Biotherapeutics and that a decision could be made within weeks on whether it might be cleared. Credit: Merck & Co. via AP, File

The European Medicines Agency said it has received a request from Merck to authorize its coronavirus antiviral, the first pill shown to treat COVID-19.

In a statement Tuesday, the EU drug regulator said it had started evaluating molnupiravir, made by Merck and Ridgeback Biotherapeutics, and that a decision could be made within weeks on whether it might be cleared.

[Last week](#), the EMA issued emergency advice saying that molnupiravir could be used to treat adults infected with the coronavirus who don't yet need extra oxygen and are at increased risk of developing severe disease.

The agency said the drug should be given as soon as possible after COVID-19 has been diagnosed and within five days of symptoms starting. It is intended to be taken twice a day for five days.

Earlier this month, [Britain](#) became the first country in the world to OK the drug. The U.K. licensed molnupiravir for adults diagnosed with COVID-19 and with at least one risk factor for severe disease.

An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb explosive outbreaks in conjunction with vaccination campaigns.

Europe is now at the epicenter of the pandemic and the World Health Organization has warned that without urgent measures, Europe could see 700,000 more COVID-19 deaths by the spring.

Molnupiravir is also pending review with regulators in the U.S., which is expected to convene an [expert panel](#) later this month to consider authorization.

Even if the pill is licensed, initial supplies will be limited. Merck has said it can produce 10 million treatment courses this year, but much of that supply has already been purchased by governments worldwide.

In October, Merck agreed to let other drugmakers produce molnupiravir and signed a [licensing agreement](#) with the U.N.-backed Medicines Patent Pool allowing its [pill](#) to be made by companies in dozens of countries.

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Merck asks EU regulator to authorize its COVID-19 pill (2021, November 23)
retrieved 4 February 2024 from
<https://medicalxpress.com/news/2021-11-merck-eu-authorize-covid-pill.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--